Jun 24, 2020 – MSDG Meeting

Abstract: Despite the growing use of mass spectrometry in biomedical research, the wide dynamic range of protein expression and varying stoichiometry of post-translational modifications represent a significant hurdle to achieving ‘unbiased’ proteome characterization. These limitations also impede our ability to identify and characterize new protein drug targets. In this presentation I will discuss our recent efforts to leverage the unique analytical performance of the timsTOF Pro platform to interrogate multiple aspects of the functional proteome. Examples will include deep proteome coverage of highly enriched, primary human cells, analysis of post-translational modifications, characterization of selective small molecule inhibitors, as well as our initial efforts to develop parallel reaction monitoring (PRM) acquisition on the timsTOF Pro for biomarker validation.